# Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

> **NCT00677326** · PHASE1,PHASE2 · TERMINATED · sponsor: **Tokyo University** · enrollment: 1 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** VEGFR1 and VEGFR2

## Key facts

- **NCT ID:** NCT00677326
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Difficulty in recruiting
- **Last updated:** 2009-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677326, "Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00677326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*